Company: SION
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001193125-25-022709
Chunk: 20

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-07
Form: 424B4
Chunk 20
---
 this prospectus and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” before deciding whether to invest in our common stock. The risks described below are not the only ones facing us. The following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the trading price of our common stock could decline, and you may lose all or part of your investment.

This prospectus also contains forward-looking statements and estimates that involve risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Our actual results could differ materially from those anticipated in our forward-looking statements as a result of specific factors, including the risks and uncertainties described below.

Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital

We are a clinical-stage biopharmaceutical company and have incurred significant operating losses since inception and anticipate that we will continue to incur significant operating losses for the foreseeable future. Our net losses were $47.3 million and $40.2 million for the years ended December 31, 2023 and 2022, respectively. We had an accumulated deficit of $165.2 million and $119.4 million as of September 30, 2024 and December 31, 2023, respectively. We may never achieve or maintain profitability.

We are a clinical-stage
biopharmaceutical company with a limited operating history. We have incurred operating losses in each year since our inception. Our net losses were $47.3 million and $40.2 million for the years ended December 31, 2023 and 2022,
respectively. We had an accumulated deficit of $165.2 million and $119.4 million as of September 30, 2024 and December 31, 2023, respectively. Substantially all of our operating losses have resulted from costs incurred in connection with
our research and development programs and from general and administrative costs associated with our operations. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’
deficit and working capital.

Since our inception in 2019, we have devoted substantially all of our efforts and financial resources to the
development of our product candidates, the continuation of ongoing clinical trials, the commencement of new clinical trials and ongoing manufacturing to support our product candidates